Skip to content

Full Endovascular vs Hybrid Repair of Common Femoral Artery Associated with Ipsilateral Concomitant Arterial Lesions in Septuagenarians Patients.

Sep 2026 · Annals of Vascular Surgery · Vol 134, pp. 236-246 · 0 citations · 20 references
Medicine

TL;DR

In septuagenarian patients, full endovascular repair of the CFA and ipsilateral concomitant lesions was associated with mid-term outcomes similar to those of hybrid surgery, while reducing hospital length of stay and perioperative complications.

Abstract

Purpose

Multilevel lower limb peripheral artery disease remains a significant healthcare challenge, particularly in an aging population. Endovascular procedures have gained increasing interest, especially in elderly patients with significant comorbidities. The aim of this study was to compare full endovascular treatment (ENDO) versus hybrid repair (HYR) for common femoral artery (CFA) lesions when combined with concomitant lower limbs lesions in septuagenarian's patients.

Methods

Between June 2016 and June 2024, 186 patients aged ≥ 70 were treated for CFA occlusive disease with iliac or femoropopliteal lesions (102 hybrid, 84 endovascular). After propensity score matching, 54 patients remained in each group. The primary endpoint was the primary sustained clinical improvement. Secondary outcomes included overall survival, major adverse limb events (MALE), primary patency, and target lesion revascularization (TLR).

Results

Overall, CFA lesions were classified as Azema I (6%), Azema II (23%), and Azema III (71%). Baseline clinical and demographic characteristics were well balanced between the groups except for age and concomitant treated lesions. ENDO group was slightly older (78 +/- 5 vs 75 +/- 5 years, p < 0.001) and had more femoropopliteal lesions (57% vs 33%; p < 0.001). Intermittent claudication was the most common clinical presentation (HYR group: 65%; ENDO group: 59%; p=0.35). The mean duration of hospitalization was significantly lower in the stenting group (5 ± 1.5 days versus 10 ± 2.5 days; p<0.001). The 30-day cumulative complication rate was higher in the hybrid group (6% vs 19%, p=0.07). At 24-months, primary sustained clinical improvement was similar between the groups (85% vs 91%, p=0.1). No significant differences were observed in global survival, MALE, primary patency, or freedom from TLR.

Conclusion

In septuagenarian patients, full endovascular repair of the CFA and ipsilateral concomitant lesions was associated with mid-term outcomes similar to those of hybrid surgery, while reducing hospital length of stay and perioperative complications. Full endovascular treatment could nonetheless be considered a valid alternative to hybrid procedures in septuagenarian patients, especially those at high surgical risk, pending confirmation in more homogeneous, prospective cohorts.

View source

Similar papers

Open access Sep 2026

Endovascular management of superficial femoral artery chronic total occlusions: Influence of lesion complexity and popliteal access on the efficacy of rotational atherectomy plus drug-coated balloon versus drug-coated balloon alone

Objectives: This study aimed to compare the safety and efficacy of rotational atherectomy combined with drug-coated balloon angioplasty (RA+DCB) versus DCB alone in patients with superficial femoral artery chronic total occlusions (SFA CTOs) and to evaluate the influence of lesion complexity and vascular access site (f...

I. Oz, Emre Karacay, Betül Ozaslan et al. · 0 citations
Open access Oct 2026

Endovascular treatment versus best medical treatment for acute anterior cerebral artery occlusion: a single-center inverse probability of treatment-weighted cohort study

Evidence regarding the benefit of endovascular treatment (EVT) for isolated acute anterior cerebral artery occlusion remains limited. We aimed to compare the efficacy and safety of EVT versus best medical treatment (BMT) in this population. We retrospectively screened consecutive patients with acute anterior...

Xiao-Lin Wan, Bao-Ming Lei, K. Tang et al. · 0 citations
Oct 2026

Early Outcomes of Physician-Modified Endurant Limbs vs Iliac Branch Devices in Narrow Common Iliac Arteries: A Retrospective Cohort Pilot Study.

OBJECTIVES To evaluate the feasibility and short-term outcomes of physician-modified Endurant limbs (PMEGs) for internal iliac artery (IIA) preservation in patients with narrow common iliac artery (CIA) anatomy, with descriptive comparison to commercially available iliac branch devices (IBDs). METHODS This retrospect...

Chayatorn Chansakaow, Termpong Reanpang, Saranat Orrapin et al. · 0 citations
Aug 2026

2-Year outcomes of endovascular therapy of popliteal artery restenosis.

Background: To assess the mid-term outcome of endovascular treatment for popliteal artery restenosis. Patients and methods: This retrospective study included patients with peripheral artery disease (Rutherford class (RC) 2-5) and popliteal artery restenosis treated between January 2007 and December 2017. Patients were...

T. Böhme, E. Noory, U. Beschorner et al. · 0 citations
Open access Sep 2026

Comparative midterm outcomes of contemporary revascularization strategies for acute lower limb ischemia: a retrospective cohort study

Acute lower limb ischaemia (ALLI) is a vascular emergency associated with high morbidity and mortality. Contemporary revascularization strategies include open surgery,endovascular intervention,and hybrid approaches,yet comparative midterm outcomes remain incompletely defined. We conducted a single - center...

Hua Zhang, Peng-Wei Guo, Bao-Xin Chen et al. · 0 citations
Open access Sep 2026

Long-term safety and efficacy of endovascular therapy in the lower extremity

Aim Endovascular therapy has become the preferred revascularization method for lower extremity arterial disease (LEAD), offering reduced procedural morbidity compared with open surgery. However, real-world data on its long-term durability and safety in complex lesions remain limited. This study aimed to evaluate the lo...

Emced Khalil · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.